Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 309

The DOI matches its Crossref record; 55 of the 55 references it cites were found in a registry or an index.

The genomic landscape of metastatic breast cancer highlights changes in mutation and signature frequencies

Open access
Angus, Lindsay, Smid, Marcel, Wilting, Saskia M., van Riet, Job, Van Hoeck, Arne, Nguyen, Luan, Nik-Zainal, Serena, Steenbruggen, Tessa G., Tjan-Heijnen, Vivianne C. G., Labots, Mariette, van Riel, Johanna M. G. H., Bloemendal, Haiko J., Steeghs, Neeltje, Lolkema, Martijn P., Voest, Emile E., van de Werken, Harmen J. G., Jager, Agnes, Cuppen, Edwin, Sleijfer, Stefan, Martens, John W. M.·2019·Nature Genetics

Abstract

The whole-genome sequencing of prospectively collected tissue biopsies from 442 patients with metastatic breast cancer reveals that, compared to primary breast cancer, tumor mutational burden doubles, the relative contributions of mutational signatures shift and the mutation frequency of six known driver genes increases in metastatic breast cancer. Significant associations with pretreatment are also observed. The contribution of mutational signature 17 is significantly enriched in patients pretreated with fluorouracil, taxanes, platinum and/or eribulin, whereas the de novo mutational signature I identified in this study is significantly associated with pretreatment containing platinum-based chemotherapy. Clinically relevant subgroups of tumors are identified, exhibiting either homologous recombination deficiency (13%), high tumor mutational burden (11%) or specific alterations (24%) linked to sensitivity to FDA-approved drugs. This study provides insights into the biology of metastatic breast cancer and identifies clinically useful genomic features for the future improvement of patient management. Whole-genome sequencing of metastatic biopsies from 442 patients with breast cancer provides insights into metastatic disease, including associations of genomic features with prior treatments and identification of therapeutic vulnerabilities.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41588-019-0507-7

Cites

55 of 55 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 55 references

Cited by

See all 309

Metadata

Authors
Angus, L., Smid, M., Wilting, S. M., van Riet, J., Van Hoeck, A., Nguyen, L., Nik-Zainal, S., Steenbruggen, T. G., Tjan-Heijnen, V. C. G., Labots, M., van Riel, J. M. G. H., Bloemendal, H. J., Steeghs, N., Lolkema, M. P., Voest, E. E., van de Werken, H. J. G., Jager, A., Cuppen, E., Sleijfer, S., & Martens, J. W. M.
Venue
Nature Genetics
Published
2019-09-30
Volume
51
Issue
10
Pages
1450-1458
ISSN
  • 1061-4036 (ISSN-L)
  • 1546-1718
OpenAlex
W2976511826
Cited by
309
References
55
FWCI
12.65
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The genomic landscape of metastatic breast cancer highlights changes in mutation and signature frequencies. https://app.cochat.ai/papers/10.1038/s41588-019-0507-7
The paper
Angus, L., Smid, M., Wilting, S. M., van Riet, J., Van Hoeck, A., Nguyen, L., Nik-Zainal, S., Steenbruggen, T. G., Tjan-Heijnen, V. C. G., Labots, M., van Riel, J. M. G. H., Bloemendal, H. J., Steeghs, N., Lolkema, M. P., Voest, E. E., van de Werken, H. J. G., Jager, A., Cuppen, E., Sleijfer, S., & Martens, J. W. M. (2019). The genomic landscape of metastatic breast cancer highlights changes in mutation and signature frequencies. Nature Genetics. https://doi.org/10.1038/s41588-019-0507-7

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.